fenoldopam has been researched along with Heart Failure in 23 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 9.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 7.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "Fenoldopam (SKF 82526 J) is a selective DA-1 receptor agonist and thus of a potential benefit for promoting afterload reduction, renal vasodilatation, and diuresis in congestive heart failure." | 7.67 | Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure. ( Jover, BF; McGrath, BP, 1988) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 7.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| "Fenoldopam (SKF-82526-J) is a new, orally available, selective, dopamine-receptor agonist with potent renal vasodilating properties (six times that of dopamine) without positive inotropic or adrenergic activity." | 6.66 | Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. ( Aronoff, RD; Leon, CA; Pratt, CM; Roberts, R; Suarez, JM; Young, JB, 1985) |
| " In 15 patients with a mean radionuclide ejection fraction of 17%, the agents were infused in a random-ordered, double-blinded, crossover, active drug-controlled protocol after optimal dosing was determined during a titration period." | 6.66 | Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside. ( Kingry, C; Leon, CA; Pratt, CM; Roberts, R; Taylor, AA; Young, JB, 1988) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 6.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 5.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients." | 5.06 | A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. ( Jeffrey, RF; Lee, MR; MacDonald, TM; Muir, AL, 1990) |
| " The novel DA1 receptor agonist fenoldopam is claiming a role in the management of hypertension, heart failure, and the preservation of renal function." | 4.78 | Dopamine and dopamine receptor agonists in cardiovascular therapy. ( Elliott, WJ; Murphy, MB, 1990) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 3.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "Fenoldopam (SKF 82526 J) is a selective DA-1 receptor agonist and thus of a potential benefit for promoting afterload reduction, renal vasodilatation, and diuresis in congestive heart failure." | 3.67 | Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure. ( Jover, BF; McGrath, BP, 1988) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 3.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| "Fenoldopam (SKF-82526-J) is a new, orally available, selective, dopamine-receptor agonist with potent renal vasodilating properties (six times that of dopamine) without positive inotropic or adrenergic activity." | 2.66 | Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. ( Aronoff, RD; Leon, CA; Pratt, CM; Roberts, R; Suarez, JM; Young, JB, 1985) |
| " In 15 patients with a mean radionuclide ejection fraction of 17%, the agents were infused in a random-ordered, double-blinded, crossover, active drug-controlled protocol after optimal dosing was determined during a titration period." | 2.66 | Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside. ( Kingry, C; Leon, CA; Pratt, CM; Roberts, R; Taylor, AA; Young, JB, 1988) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 2.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (43.48) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nussmeier, NA | 1 |
| Cohen, MG | 1 |
| Allie, DE | 1 |
| Hebert, CJ | 1 |
| Walker, CM | 1 |
| Pucelikova, T | 1 |
| Dangas, G | 1 |
| Mehran, R | 1 |
| Patel, JJ | 1 |
| Mitha, AS | 1 |
| Sareli, P | 1 |
| de Vaal, JB | 1 |
| Smit, AJ | 2 |
| Blanchett, DG | 1 |
| Green, JA | 3 |
| Nara, A | 1 |
| Pospisil, R | 2 |
| Jarvis, RC | 3 |
| Kasmer, RJ | 3 |
| Boyle, DA | 1 |
| Cyronak, MJ | 1 |
| Corder, CN | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Murphy, MB | 1 |
| Elliott, WJ | 1 |
| Munger, MA | 1 |
| Benotti, JR | 1 |
| Nara, AR | 2 |
| McCue, JE | 1 |
| Pospisil, RA | 1 |
| MacDonald, TM | 1 |
| Jeffrey, RF | 1 |
| Muir, AL | 1 |
| Lee, MR | 1 |
| Holcslaw, TL | 1 |
| Beck, TR | 1 |
| Casagrande, C | 1 |
| Merlo, L | 1 |
| La Regina, A | 1 |
| Jover, BF | 1 |
| McGrath, BP | 1 |
| Hassan, E | 1 |
| Carey, RA | 1 |
| Jacob, L | 1 |
| Hasenfuss, G | 1 |
| Just, H | 1 |
| Strocchi, E | 1 |
| Tartagni, F | 1 |
| Malini, PL | 1 |
| Valtancoli, G | 1 |
| Ambrosioni, E | 1 |
| Pasinelli, F | 1 |
| Riva, E | 1 |
| Fuccella, LM | 1 |
| Goldberg, LI | 1 |
| Rajfer, SI | 1 |
| Young, JB | 2 |
| Leon, CA | 2 |
| Pratt, CM | 2 |
| Suarez, JM | 1 |
| Aronoff, RD | 1 |
| Roberts, R | 2 |
| Shebuski, RJ | 1 |
| Smith, JM | 1 |
| Ruffolo, RR | 1 |
| Kingry, C | 1 |
| Taylor, AA | 1 |
| Francis, GS | 1 |
| Wilson, BC | 1 |
| Rector, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pre-existing Microalbuminuria Predicting Contrast-induced Acute Kidney Injury (CIAKI) Following Coronary Angiography (CAG)[NCT02808845] | 800 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Early Detection of Contrast Induced Nephropathy After Coronary Angiography : Predictive Value of Osteopontin[NCT05547581] | 155 participants (Anticipated) | Observational | 2022-12-07 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for fenoldopam and Heart Failure
| Article | Year |
|---|---|
Improving perioperative outcomes in patients with end-stage heart failure.
Topics: Cardiac Surgical Procedures; Dopamine Agonists; Fenoldopam; Heart Failure; Heart Transplantation; He | 2003 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Dopamine in heart failure and critical care.
Topics: Cardiotonic Agents; Controlled Clinical Trials as Topic; Critical Care; Deoxyepinephrine; Dopamine; | 2000 |
Dopamine and dopamine receptor agonists in cardiovascular therapy.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Biological Availability; Blood Pressure; | 1990 |
Clinical experience with intravenous fenoldopam.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Cardiovascular System; Chemical Phenomen | 1990 |
Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Deoxyepinephrine; Dopamine; Dop | 1990 |
The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
Topics: Benzazepines; Deoxyepinephrine; Dobutamine; Dopamine; Dopamine Agents; Fenoldopam; Heart Failure; Hu | 1989 |
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D | 1989 |
5 trials available for fenoldopam and Heart Failure
| Article | Year |
|---|---|
Intravenous fenoldopam infusion in severe heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Diuretics; Dopamine Agents; Dose- | 1993 |
The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Adult; Aged; Biolo | 1991 |
A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Body Weight; Coronary Disease; Dop | 1990 |
Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure.
Topics: Benzazepines; Fenoldopam; Heart Failure; Hemodynamics; Humans; Vascular Resistance | 1985 |
Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside.
Topics: Adult; Benzazepines; Double-Blind Method; Female; Fenoldopam; Ferricyanides; Heart Failure; Hemodyna | 1988 |
10 other studies available for fenoldopam and Heart Failure
| Article | Year |
|---|---|
First experience with intra-renal fenoldopam in a patient with heart failure.
Topics: Aged; Cardiac Catheterization; Catheterization; Electrocardiography; Equipment Design; Equipment Saf | 2005 |
Multifactorial acute renal failure treated with percutaneous targeted renal therapy (TRT): a case of "dialysis rescue".
Topics: Acute Kidney Injury; Administration, Cutaneous; Aged; Catheterization; Diabetic Nephropathies; Fenol | 2007 |
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Aged, 80 and over; Drug Tol | 1990 |
Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure.
Topics: Animals; Benzazepines; Cardiac Output; Catecholamines; Cerebrovascular Circulation; Disease Models, | 1988 |
Continuous monitoring of mixed venous oxygen saturation as an indicator of pharmacologic intervention.
Topics: Benzazepines; Cardiac Catheterization; Cardiac Output; Fenoldopam; Heart Failure; Humans; Male; Midd | 1989 |
Interaction study of fenoldopam--digoxin in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Digoxin; Dopamine Agents; D | 1989 |
Dopamine receptors: applications in clinical cardiology.
Topics: Administration, Oral; Arrhythmias, Cardiac; Benzazepines; Bromocriptine; Deoxyepinephrine; Fenoldopa | 1985 |
Comparison of the renal and pulmonary hemodynamic effects of fenoldopam, dobutamine, dopamine and norepinephrine in the anesthetized dog.
Topics: Animals; Benzazepines; Cardiotonic Agents; Dobutamine; Dogs; Dopamine; Female; Fenoldopam; Heart Fai | 1988 |
Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.
Topics: Administration, Oral; Aldosterone; Arginine Vasopressin; Benzazepines; Fenoldopam; Heart Failure; He | 1988 |